ERBB2 and neoplasm: Promising results were also seen in a fully virulent oHSV retargeted to human ErbB-2 to deliver murine IL-12 in murine glioblastoma models, with an unprecedented complete eradication of the tumor in 30% of subjects, which is something rarely seen with the most commonly used mutated or attenuated OVs [137].